Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May 26;20(8):20.
doi: 10.1007/s11908-018-0628-7.

Benefits and Risks of Statin Therapy in the HIV-Infected Population

Mosepele Mosepele  1   2   3 , Onkabetse J Molefe-Baikai  4 , Steven K Grinspoon  5 , Virginia A Triant  6
Affiliations
Review

Benefits and Risks of Statin Therapy in the HIV-Infected Population

Mosepele Mosepele et al. Curr Infect Dis Rep. .

Abstract

Purpose of review: HIV-infected patients face an increased risk for cardiovascular disease (CVD), estimated at 1.5- to 2-fold as compared to HIV-uninfected persons. This review provides a recent (within preceding 5 years) summary of the role of statin therapy and associated role in CVD risk reduction among HIV-infected patients on anti-retroviral therapy.

Recent findings: Statins remain the preferred agents for reducing risk for CVD among HIV-infected populations based on guidance extrapolated from general population (HIV-uninfected) cholesterol treatment guidelines across different settings globally. However, HIV-infected patients are consistently under prescribed statin therapy when compared to their HIV-uninfected counterparts. The most commonly studied statins in clinical care and small randomized and cohort studies have been rosuvastatin and atorvastatin. Both agents are preferred for their potent lipid-lowering effects and their favorable or neutral pleotropic effects on chronic inflammation, renal function, and hepatic steatosis among others. However, growing experience with the newer glucuronidated pitavastatin suggests that this agent has virtually no adverse drug interactions with ART or effects on glucose metabolism-all marked additional benefits when compared with rosuvastatin and atorvastatin while maintaining comparable anti-lipid effects. Pitavastatin is therefore the statin of choice for the ongoing largest trial (6500 participants) to test the benefits of statin therapy among HIV-infected adults. Statins are underutilized in the prevention of CVD in HIV-infected populations based on criteria in established cholesterol guidelines. There is a potential role for statin therapy for HIV-infected patients who do not meet guideline criteria which will be further delineated through ongoing clinical trials.

Keywords: Atherosclerotic cardiovascular disease; HIV; Inflammation; Prevention; Statin.

PubMed Disclaimer

References

    1. Endo A, The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res, 1992. 33(11): p. 1569–82. - PubMed
    1. Sirtori CR, The pharmacology of statins. Pharmacol Res, 2014. 88: p. 3–11. - PubMed
    1. Brunengraber H, New mechanisms by which statins lower plasma cholesterol. J Lipid Res, 2016. 57(8): p. 1325–6. - PMC - PubMed
    1. Schonewille M, et al. , Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice. J Lipid Res, 2016. 57(8): p. 1455–64. - PMC - PubMed
    1. Gili S, et al. , Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J, 2016. 37(48): p. 3600–3609. - PubMed

LinkOut - more resources